Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference
Passage Bio, a clinical stage genetic medicines company focused on neurodegenerative diseases, has announced its participation in Chardan's 8th Annual Genetic Medicines Conference. Will Chou, M.D., the company's president and CEO, will present on Tuesday, October 1, 2024, at 8:30 a.m. ET.
The presentation will be accessible via a live webcast on the Investors & Media section of Passage Bio's website at investors.passagebio.com. For those unable to attend the live event, a replay will be available for 30 days following the presentation.
Passage Bio is traded on the NASDAQ under the ticker symbol PASG.
Passage Bio, un'azienda di medicinali genetici in fase clinica che si concentra sulle malattie neurodegenerative, ha annunciato la sua partecipazione alla 8a Conferenza Annuale sui Medicinali Genetici di Chardan. Will Chou, M.D., presidente e CEO dell'azienda, presenterà martedì 1 ottobre 2024 alle 8:30 ET.
La presentazione sarà accessibile tramite un webcast dal vivo nella sezione Investitori e Media del sito web di Passage Bio su investors.passagebio.com. Per coloro che non possono partecipare all'evento dal vivo, sarà disponibile una registrazione per 30 giorni dopo la presentazione.
Passage Bio è quotata sul NASDAQ con il simbolo ticker PASG.
Passage Bio, una empresa de medicamentos genéticos en etapa clínica enfocada en enfermedades neurodegenerativas, ha anunciado su participación en la 8ª Conferencia Anual de Medicamentos Genéticos de Chardan. Will Chou, M.D., presidente y CEO de la empresa, presentará el martes 1 de octubre de 2024 a las 8:30 a.m. ET.
La presentación será accesible a través de un webcast en vivo en la sección de Inversores y Medios del sitio web de Passage Bio en investors.passagebio.com. Para aquellos que no puedan asistir al evento en vivo, habrá una repetición disponible por 30 días después de la presentación.
Passage Bio cotiza en el NASDAQ bajo el símbolo de ticker PASG.
Passage Bio, 신경퇴행성 질환에 집중하는 임상 단계 유전자 의약품 회사, Chardan의 제8회 연례 유전자 의약품 회의에 참가한다고 발표했습니다. Will Chou, M.D.는 회사의 사장 겸 CEO로서 2024년 10월 1일 화요일 오전 8시 30분 ET에 발표할 예정입니다.
발표는 Passage Bio 웹사이트의 투자자 및 미디어 섹션에서 실시간 웹캐스트를 통해 접근할 수 있습니다. 생중계에 참석할 수 없는 분들을 위해, 발표 후 30일 동안 재방송이 제공됩니다.
Passage Bio는 NASDAQ에서 PASG라는 티커 기호로 거래됩니다.
Passage Bio, une entreprise de médicaments génétiques en phase clinique axée sur les maladies neurodégénératives, a annoncé sa participation à la 8ème Conférence Annuelle sur les Médicaments Génétiques de Chardan. Will Chou, M.D., le président et CEO de l'entreprise, fera une présentation le mardi 1er octobre 2024 à 8h30 ET.
La présentation sera accessible par le biais d'un webcast en direct dans la section Investisseurs et Médias du site web de Passage Bio à investors.passagebio.com. Pour ceux qui ne peuvent pas assister à l'événement en direct, un replay sera disponible pendant 30 jours après la présentation.
Passage Bio est coté sur le NASDAQ sous le symbole boursier PASG.
Passage Bio, ein Unternehmen für genetische Arzneimittel in der klinischen Phase, das sich auf neurodegenerative Erkrankungen konzentriert, hat seine Teilnahme an der 8. jährlichen Konferenz für genetische Arzneimittel von Chardan bekannt gegeben. Will Chou, M.D., der Präsident und CEO des Unternehmens, wird am Dienstag, den 1. Oktober 2024 um 8:30 Uhr ET präsentieren.
Die Präsentation wird über einen Live-Webcast im Bereich Investoren und Medien auf der Website von Passage Bio unter investors.passagebio.com zugänglich sein. Für diejenigen, die nicht an der Live-Veranstaltung teilnehmen können, wird eine Aufzeichnung 30 Tage nach der Präsentation verfügbar sein.
Passage Bio wird an der NASDAQ unter dem Tickersymbol PASG gehandelt.
- None.
- None.
PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at Chardan’s 8th Annual Genetic Medicines Conference on Tuesday, October 1, 2024 at 8:30 a.m. ET.
A live webcast of the event will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation will be available for 30 days following the event.
About Passage Bio
Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression.
To learn more about Passage Bio and our steadfast commitment to protecting patients and families against loss in neurodegenerative conditions, please visit: www.passagebio.com.
For further information, please contact:
Investors:
Stuart Henderson
Passage Bio
267.866.0114
shenderson@passagebio.com
Passage Bio Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312.961.2502
mikebeyer@sambrown.com
FAQ
When is Passage Bio (PASG) presenting at Chardan's 8th Annual Genetic Medicines Conference?
Who will be presenting for Passage Bio (PASG) at the Chardan conference?
How can I watch Passage Bio's (PASG) presentation at the Chardan conference?
For how long will the replay of Passage Bio's (PASG) presentation be available?
What is Passage Bio's (PASG) focus as a genetic medicines company?
